본문으로 건너뛰기
← 뒤로

Protocol to investigate the biochemical details of immune checkpoint ligand/receptor ubiquitination using in vitro ubiquitination assay.

STAR protocols 2025 Vol.6(4) p. 104150

Xie G, Gao L, Tian L, Li X, Zheng T, Yu X, Jiang H, Chen Z

📝 환자 설명용 한 줄

The activity and stability of immune checkpoint ligands/receptors, including PD-L1 and PD-1, are tightly regulated by ubiquitination.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Xie G, Gao L, et al. (2025). Protocol to investigate the biochemical details of immune checkpoint ligand/receptor ubiquitination using in vitro ubiquitination assay.. STAR protocols, 6(4), 104150. https://doi.org/10.1016/j.xpro.2025.104150
MLA Xie G, et al.. "Protocol to investigate the biochemical details of immune checkpoint ligand/receptor ubiquitination using in vitro ubiquitination assay.." STAR protocols, vol. 6, no. 4, 2025, pp. 104150.
PMID 41108680

Abstract

The activity and stability of immune checkpoint ligands/receptors, including PD-L1 and PD-1, are tightly regulated by ubiquitination. Here, we present a protocol for detecting ubiquitination of the cytoplasmic domain of PD-L1 by various E3 ligases and evaluating the effects of phosphorylation and membrane association on PD-L1 ubiquitination. We describe steps for expressing and purifying recombinant cytoplasmic domain of PD-L1 and related ubiquitination enzymes, preparing liposomes from DC2.4 cells, and detecting PD-L1 ubiquitination using in vitro ubiquitination assays. For complete details on the use and execution of this protocol, please refer to Xie et al..

MeSH Terms

Ubiquitination; Humans; B7-H1 Antigen; Ubiquitin-Protein Ligases; Ligands; Liposomes; Animals

같은 제1저자의 인용 많은 논문 (2)